EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers

Daniela Meco, Giorgio Attinà iD, Stefano Mastrangelo, Pierluigi Navarra, Antonio Ruggiero iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24021334 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Daniela Meco und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy. Hauptthemen laut MEDLINE: Antineoplastic Agents, Brain Neoplasms, Head and Neck Neoplasms, Anti-Infective Agents. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione per l’Oncologia Pediatrica (FOP).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Repurposing approved non-antitumor drugs is a promising and affordable strategy in drug discovery to identify new therapeutic uses different from the original medical indication that may help increase the number of possible, effective anticancer drugs. The use of drugs in ways other than their original FDA-approved indications could offer novel avenues such as bypassing the chemoresistance and recurrence seen with conventional therapy and treatment; moreover, it can offer a safe and economic strategy for combination therapy. Recent works have demonstrated the anticancer properties of the FDA-approved drug Mebendazole. This synthetic benzimidazole proved effective against a broad spectrum of intestinal Helminthiasis. Mebendazole can penetrate the blood–brain barrier and has been shown to inhibit the malignant progression of glioma by targeting signaling pathways related to cell proliferation, apoptosis, or invasion/migration, or by increasing the sensitivity of glioma cells to conventional chemotherapy or radiotherapy. Moreover, several preclinical models and ongoing clinical trials explore the efficacy of Mebendazole in multiple cancers, including acute myeloid leukemia, brain cancer, oropharyngeal squamous cell carcinoma, breast cancer, gastrointestinal cancer, lung carcinoma, adrenocortical carcinoma, prostate cancer, and head and neck cancer. The present review summarizes central literature regarding the anticancer effects of MBZ in cancer cell lines, animal tumor models, and clinical trials to suggest possible strategies for safe and economical combinations of anticancer therapies in brain cancer. Mebendazole might be an excellent candidate for the treatment of brain tumors because of its efficacy both when used as monotherapy and in combination as an enhancement to standard chemotherapeutics and radiotherapy, due to its effectiveness on tumor angiogenesis inhibition, cell cycle arrest, apoptosis induction, and targeting of critical pathways involved in cancer such as Hedgehog signaling. Therefore, attention to MBZ repurposing has recently increased because of its potential therapeutic versatility and significant clinical implications, such as reducing medical care costs and optimizing existing therapies. Using new treatments is essential, particularly when current therapeutics for patients with brain cancer fail.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBrain NeoplasmsHead and Neck NeoplasmsAnti-Infective AgentsGliomaMaleAnimalsMebendazoleAntiparasitic AgentsCell Line, TumorHedgehog Proteins

Stichwörter der Autor:innen

Mebendazoleantitumor therapybenzimidazolebrain cancerdrug repurposing

Substanzen

MebendazoleAntiparasitic AgentsHedgehog ProteinsAntineoplastic AgentsAnti-Infective Agents

Autor:innen und Institutionen

  • Pediatric Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
  • Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Department of Healthcare Surveillance and Bioethics, Section of Pharmacology, Università Cattolica del Sacro Cuore-Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.

ORCID-Profile: Giorgio Attinà, Antonio Ruggiero

Förderung

  • Fondazione per l’Oncologia Pediatrica (FOP)

Zitieren

APA

Meco, D., Attinà, G., Mastrangelo, S., Navarra, P., & Ruggiero, A. (2023). Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021334

Vancouver

Meco D, Attinà G, Mastrangelo S, Navarra P, Ruggiero A. Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24021334

BibTeX
@article{Meco2023,
  author = {Meco, Daniela and Attinà, Giorgio and Mastrangelo, Stefano and Navarra, Pierluigi and Ruggiero, Antonio},
  title = {Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24021334}
}
Kostenlos starten →